Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Fuster

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
Journal of Clinical Medicine|February 25, 2022
Abuse Potential of Cathinones in Humans: A Systematic ReviewLourdes Poyatos, Adrián Torres, Esther Papaseit, et al.
AIDS (London, England)|April 20, 2004
Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approachesAngel Luis Ballesteros, Sandra Franco, Daniel Fuster, et al.
Molecular & Cellular Proteomics : MCP|April 15, 2008
Monitoring protein-protein interactions between the mammalian integral membrane transporters and PDZ-interacting partners using a modified split-ubiquitin membrane yeast two-hybrid systemSerge M Gisler, Saranya Kittanakom, Daniel Fuster, et al.
BMC Infectious Diseases|April 16, 2022
Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004-2018Lourdes Domínguez-Domínguez, Marta Rava, Otilia Bisbal, et al.
Journal of Clinical Medicine|February 26, 2025
Is There an Association Between Cigarette Smoking and Advanced Liver Fibrosis in Smokers with HIV, Heavy Drinking and High Prevalence of HCV?Daniel Fuster, Kaku So-Armah, Debbie M Cheng, et al.
Plos One|June 28, 2019
Zinc deficiency and advanced liver fibrosis among HIV and hepatitis C co-infected anti-retroviral naïve persons with alcohol use in RussiaJoshua A Barocas, Kaku So-Armah, Debbie M Cheng, et al.
Alcohol, Clinical & Experimental Research|May 8, 2024
Clinical features of individuals with laboratory values suggestive of advanced liver fibrosis when first treated for alcohol use disorderPaola Zuluaga, Daniel Fuster, Rafael Blanes, et al.
Drug and Alcohol Dependence|March 9, 2023
Associations of hypomagnesemia in patients seeking a first treatment of alcohol use disorderAnna Hernández-Rubio, Arantza Sanvisens, Lucía Barbier-Torres, et al.
Antiviral Therapy|January 18, 2005
Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or bothAngel Luis Ballesteros, Oscar Miró, Sònia López, et al.
Antiviral Therapy|November 30, 2005
Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapyDaniel Fuster, Jaime A Huertas, Guadalupe Gómez, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
Journal of Clinical Medicine|February 25, 2022
Abuse Potential of Cathinones in Humans: A Systematic ReviewLourdes Poyatos, Adrián Torres, Esther Papaseit, et al.
AIDS (London, England)|April 20, 2004
Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approachesAngel Luis Ballesteros, Sandra Franco, Daniel Fuster, et al.
Molecular & Cellular Proteomics : MCP|April 15, 2008
Monitoring protein-protein interactions between the mammalian integral membrane transporters and PDZ-interacting partners using a modified split-ubiquitin membrane yeast two-hybrid systemSerge M Gisler, Saranya Kittanakom, Daniel Fuster, et al.
BMC Infectious Diseases|April 16, 2022
Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004-2018Lourdes Domínguez-Domínguez, Marta Rava, Otilia Bisbal, et al.
Journal of Clinical Medicine|February 26, 2025
Is There an Association Between Cigarette Smoking and Advanced Liver Fibrosis in Smokers with HIV, Heavy Drinking and High Prevalence of HCV?Daniel Fuster, Kaku So-Armah, Debbie M Cheng, et al.
Plos One|June 28, 2019
Zinc deficiency and advanced liver fibrosis among HIV and hepatitis C co-infected anti-retroviral naïve persons with alcohol use in RussiaJoshua A Barocas, Kaku So-Armah, Debbie M Cheng, et al.
Alcohol, Clinical & Experimental Research|May 8, 2024
Clinical features of individuals with laboratory values suggestive of advanced liver fibrosis when first treated for alcohol use disorderPaola Zuluaga, Daniel Fuster, Rafael Blanes, et al.
Drug and Alcohol Dependence|March 9, 2023
Associations of hypomagnesemia in patients seeking a first treatment of alcohol use disorderAnna Hernández-Rubio, Arantza Sanvisens, Lucía Barbier-Torres, et al.
Antiviral Therapy|January 18, 2005
Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or bothAngel Luis Ballesteros, Oscar Miró, Sònia López, et al.
Antiviral Therapy|November 30, 2005
Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapyDaniel Fuster, Jaime A Huertas, Guadalupe Gómez, et al.
Pageof 10